Preventing β-amyloid Fibrillization and Deposition
Author Information
Author(s): Wisniewski Thomas, Sadowski Martin
Primary Institution: New York University School of Medicine
Hypothesis
Can β-sheet breakers and pathological chaperone inhibitors effectively prevent β-amyloid aggregation in Alzheimer's disease?
Conclusion
Therapeutic strategies targeting β-amyloid aggregation show promise in preventing Alzheimer's disease pathology.
Supporting Evidence
- Compounds like β-sheet breakers can prevent the aggregation of β-amyloid in vitro.
- Interventions that block soluble Aβ aggregation have shown effectiveness in animal models.
- Early detection of Alzheimer's pathology can enhance the effectiveness of these therapeutic strategies.
Takeaway
Scientists are trying to stop a harmful protein from clumping together in the brain, which can help prevent Alzheimer's disease.
Methodology
The study reviews various compounds that inhibit β-amyloid aggregation and their effects in animal models.
Limitations
The clinical data from some trials did not provide clear benefits in larger populations.
Participant Demographics
Patients with mild to moderate Alzheimer's disease were included in the clinical trials.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website